Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 4/20 | 0.36 |
| ▸ | ACACB | O00763 | 6/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17370266 | 0.89 | ELANE (0.43) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370262 | 0.88 | ELANE (0.44) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370575 | 0.86 | ELANE (0.40) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370576 | 0.86 | ELANE (0.40) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370573 | 0.86 | ELANE (0.40) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370424 | 0.85 | THRB (0.40) | THRBACACBFFAR1THRA | |
| SCHEMBL17370571 | 0.85 | ELANE (0.39) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370390 | 0.85 | THRB (0.36) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370415 | 0.85 | POLB (0.32) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL17370387 | 0.85 | POLB (0.31) | POLBAPEX1HTTTDP1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708534-B2 | Polymerizable compound having triple bond, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9708534-B2 | Polymerizable compound having triple bond, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150376505-A1 | POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376505-A1 | POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376505-A1 | POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CCNT1, CCNA1, CCND1 | POLB 2371/4885APEX1 412/4885HTT 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.